ReviewInternational journal of molecular sciences2016
Optical Coherence Tomography and Magnetic Resonance Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Smoldering neuroinflammation in progressive multiple sclerosis: mechanisms, imaging biomarkers, and therapeutic opportunities.Frontiers in immunology · 2026Review
- Comparison of thickness changes in retinal nerve fibre layer in Leber's hereditary optic neuropathy patients with 11778, 14484 and 3460 mutations.Translational pediatrics · 2025Article
- Exploration of the Value of Optical Coherence Tomography (OCT) and OCT Angiography in Differentiating Between Major Depressive Disorder and Borderline Personality Disorder.International journal of methods in psychiatric research · 2025Article
- Anterograde and trans-synaptic neurodegeneration in aquaporin-4-antibody neuromyelitis optica spectrum disorder patients with a history of transverse myelitis.Brain communications · 2025Article
- Diagnosis of multiple sclerosis using optical coherence tomography supported by explainable artificial intelligence.Eye (London, England) · 2024Article
- Exploring the role of macular thickness as a potential early biomarker of neurodegeneration in acute schizophrenia.International ophthalmology · 2021Article
- Retinal changes in amyotrophic lateral sclerosis: looking at the disease through a new window.Journal of neurology · 2021Review
- Dynamics of Central Remyelination and Treatment Evolution in a Model of Multiple Sclerosis with Optic Coherence Tomography.International journal of molecular sciences · 2021Article
- Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders.European radiology · 2020Article
- MS optic neuritis-induced long-term structural changes within the visual pathway.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Retinal ganglion cell-inner plexiform layer thickness is nonlinearly associated with cognitive impairment in the community-dwelling elderly.Alzheimer's & dementia (Amsterdam, Netherlands) · 2019Article
- Retinal correlates of neurological disorders.Therapeutic advances in chronic disease · 2019Review
- Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS.Multiple sclerosis (Houndmills, Basingstoke, England) · 2018Article
- Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system.The EPMA journal · 2017Review
- The Contribution of Optical Coherence Tomography in Neuromyelitis Optica Spectrum Disorders.Frontiers in neurology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irreversible disability in multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) is largely attributed to neuronal and axonal degeneration, which, along with inflammation, is one of the major pathological hallmarks of these diseases. Optical coherence tomography (OCT) is a non-invasive imaging tool that has been used in MS, NMOSD, and other diseases to quantify damage to the retina, including the ganglion cells and their axons. The fact that these are the only unmyelinated axons within the central nervous system (CNS) renders the afferent visual pathway an ideal model for studying axonal and neuronal degeneration in neurodegenerative diseases. Structural magnetic resonance imaging (MRI) can be used to obtain anatomical information about the CNS and to quantify evolving pathology in MS and NMOSD, both globally and in specific regions of the visual pathway including the optic nerve, optic radiations and visual cortex. Therefore, correlations between brain or optic nerve abnormalities on MRI, and retinal pathology using OCT, may shed light on how damage to one part of the CNS can affect others. In addition, these imaging techniques can help identify important differences between MS and NMOSD such as disease-specific damage to the visual pathway, trans-synaptic degeneration, or pathological changes independent of the underlying disease process. This review focuses on the current knowledge of the role of the visual pathway using OCT and MRI in patients with MS and NMOSD. Emphasis is placed on studies that employ both MRI and OCT to investigate damage to the visual system in these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.